Wegovy and Vision Loss: The Science

Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist manufactured by Novo Nordisk, FDA-approved in 2021 for chronic weight management in adults with obesity or overweight with a weight-related condition. It contains the same active ingredient (semaglutide) as Ozempic but at a higher dose, specifically engineered for weight loss rather than diabetes control.

The Harvard study published in JAMA Ophthalmology (July 2024) analyzed patients taking semaglutide for obesity separately from those taking it for diabetes — and found an even more striking result: obesity patients taking semaglutide had a 7.64x higher risk of NAION compared to those taking other weight-loss medications.

The Wegovy distinction: Among GLP-1 drugs studied for NAION risk, obesity patients on Wegovy showed nearly double the elevated NAION odds compared to diabetes patients on Ozempic (7.64x vs. 4.28x). This may relate to Wegovy's higher semaglutide dose or differences in the patient population.

What is Wegovy?

Wegovy contains semaglutide at 2.4mg — roughly twice the maximum dose used in Ozempic. It is administered as a weekly subcutaneous injection with a dose escalation schedule (starting at 0.25mg and titrating up over 16+ weeks to the 2.4mg maintenance dose).

Wegovy became a cultural phenomenon following its FDA approval, widely known as the "new weight loss drug" that produces substantial weight reduction — clinical trials showed 15–17% average body weight loss over 68 weeks. This resulted in massive off-label and on-label prescribing, exposing many more patients to potential NAION risk.

Why Is the NAION Risk Higher for Wegovy Users?

Researchers hypothesize several reasons why obesity patients on semaglutide may have even higher NAION risk:

  • Higher dose: Wegovy uses a higher maximum dose of semaglutide than Ozempic, potentially producing more pronounced vascular effects on optic nerve blood supply
  • Faster weight loss: Rapid fluid redistribution and blood pressure changes during aggressive weight loss may affect intraocular pressure and optic nerve perfusion
  • Patient population: Obesity itself is associated with sleep apnea and metabolic syndrome — independent NAION risk factors — and rapid weight loss may paradoxically affect these conditions unpredictably
  • Longer duration of use: Wegovy is typically prescribed for long-term use, increasing cumulative exposure

Novo Nordisk's Failure to Update US Labels

As of March 2026, Novo Nordisk has not updated Wegovy's US prescribing information or patient medication guide to include NAION as a potential adverse event. Plaintiffs allege this constitutes a failure to warn under FDA regulations and applicable state product liability law.

The company has faced pressure from ophthalmologists and the medical community to update its labels following the Harvard study. The continued failure to act despite this scientific evidence is a central allegation in MDL 3163.

Wegovy Lawsuit Eligibility

To qualify for a Wegovy NAION lawsuit:

  1. You had a prescription for Wegovy (semaglutide 2.4mg) for any reason
  2. You were diagnosed with NAION by an ophthalmologist
  3. Vision loss occurred during or after taking Wegovy
  4. You had not previously been diagnosed with NAION
  5. You are within your state's statute of limitations
Check Your Eligibility Free →

Related Cases: Ozempic vs. Wegovy Claims

Both Ozempic and Wegovy NAION claims are consolidated in MDL 3163 and are being handled by the same plaintiffs' leadership team. If you took both drugs at different times, your attorney can evaluate your claim under both.

See also: